DeepMed Research

Jiangsu Simcere Pharmaceutical Co,. Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SIM0505 for injection

First Posted Date: 2025-01-24

Last Posted Date: 2025-05-20

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 172

Registration Number: NCT06792552

Locations: 🇨🇳
The first medical center of PLA general hospital, Beijing, Beijing, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
HunanCancer Hospital, Changsha, Hunan, China

and more 3 locations

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SIM0508 Tablets
Drug: SIM0508 in combination with olaparib

First Posted Date: 2024-11-13

Last Posted Date: 2025-01-07

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 130

Registration Number: NCT06686745

Locations: 🇨🇳
Chongqing Cancer Hospital, Chongqing, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE)

Phase 3

Recruiting

Conditions: Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: Everolimus (Afinitor®)
Drug: SIM0270
Drug: Exemestane tablets
Drug: Fulvestrant injection

First Posted Date: 2024-11-08

Last Posted Date: 2024-12-04

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 460

Registration Number: NCT06680921

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Mass Balance Clinical Trial of SIM0270

Phase 1

Active, not recruiting

Conditions: Healthy Participants

Interventions: Drug: [14C] SIM0270 Oral Preparation

First Posted Date: 2024-10-23

Last Posted Date: 2024-11-27

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 6

Registration Number: NCT06654791

Locations: 🇨🇳
The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China

Evaluate the Effects of Food on the Pharmacokinetics of SIM0270

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: SIM0270

First Posted Date: 2024-08-02

Last Posted Date: 2024-12-02

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT06536036

Locations: 🇨🇳
The First Affiliated Hospital of Shandong First Medical University, Jinan, Shandong, China

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: SIM0500

First Posted Date: 2024-04-19

Last Posted Date: 2025-03-03

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 130

Registration Number: NCT06375044

Locations: 🇺🇸
Dana Farber Cancer institution, Boston, Massachusetts, United States
🇺🇸
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute, New York, New York, United States

and more 5 locations

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: SIM0501 in combination with olaparib
Drug: SIM0501 Tablets

First Posted Date: 2024-03-26

Last Posted Date: 2024-04-02

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 176

Registration Number: NCT06331559

Locations: 🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China

Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Daridorexant

First Posted Date: 2024-03-22

Last Posted Date: 2024-03-22

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT06326723

Locations: 🇨🇳
Nanjing Drum Tower hospital, Nanjing, Jiangsu, China

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Phase 1

Recruiting

Conditions: Non-Muscle-Invasive Bladder Cancer (NMIBC)

Interventions: Drug: SIM0237
Drug: SIM0237 and BCG

First Posted Date: 2024-01-02

Last Posted Date: 2025-01-15

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 152

Registration Number: NCT06186414

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang, China
🇨🇳
Renmin Hospital of Wuhan University, Wuhan, Hubei, China
🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China

and more 11 locations

To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: SIM0278 Injection/Placebo

First Posted Date: 2023-09-01

Last Posted Date: 2024-04-10

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 84

Registration Number: NCT06022354

Locations: 🇨🇳
Affiliated Hospital of Qingdao University, Qingdao, China, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy